Shots:The US FDA has approved label expansion of Farapulse PFA System to incl. treatment of drug-refractory, symptomatic persistent atrial fibrillation (AF)Approval was backed by P-I data from the ADVANTAGE AF trial, which met safety & effectiveness endpoints in 260 pts intolerant to at least Class I/III anti-arrhythmic drug across 43 global sites; data…
Shots: Driven by continuous innovation, the MedTech sector is evolving rapidly to enhance preventive, diagnostic, and therapeutic capabilities in healthcareIn 2023, the global MedTech market was valued at $668.2B and is projected to reach $989.1B by 2033, growing at a CAGR of approximately 4%. Medtronic led the industry with a revenue of $33.12B, followed…
Shots:Boston Scientific entered into a definitive agreement to acquire SoniVie Ltd. to expand its interventional cardiology therapies offerings
Currently, the company holds an equity stake of approx. 10%, and for the remaining 90% stake, the company will pay approx. $360M upfront and up to $180M regulatory milestones; for 100% stake, the amount sums…
Shots:Boston Scientific has agreed to acquire Bolt Medical, strengthening its cardiovascular portfolio with the addition of Bolt IVL system for coronary & peripheral disease. Deal is expected to close in H1’25
Boston, an investor with a 26% equity stake in Bolt Medical, is acquiring the rest 74% for $443M upfront & up to…
Shots:The second quarter of 2024 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The highlight of the quarter was Vertex’ acquisition of Alpine Immune Sciences for ~$4.9BThis quarter also showcased multiple clinical trial results including Moderna’s P-III Study Data of mRNA-1283 Vaccine to Prevent COVID-19…
Shots:Michael discussed the closure of its acquisition of Apollo Endosurgery. He emphasized how this acquisition will broaden Boston Scientific's ELS portfolio, particularly in closure and suturing, while entering the endobariatric marketHe also talked about how the Apollo Endosurgery products will be integrated into Boston Scientific's existing endoluminal surgery (ELS) portfolioThe interview shows…
Shots:Driven by constant innovation and life-changing technological advances, medical device companies have integrated a holistic approach to diagnosis and therapeutics. Bolstered by the inch-perfect result and cutting-edge technology, gradually medical devices have got profoundly embedded in our livesWith a global market value of $562.6B in 2022, medical device companies are anticipated to touch…
Despite the severe impact of the Covid-19 pandemic in 2020, the medical device market continued to emerge with patients' more significant needs and emerging diseases In 2021, the medical device markets continued to supply personal protective equipment for the pandemic and new technological developments. Medtronic remains at the top of the ledger with total revenue…
In an interview with PharmaShots, Ron Morton, Chief Medical Officer, Vice President of Medical Affairs, UroPH at Boston Scientific shares his views on Rezūm Water Vapor Therapy to reduces the size of the prostate and provides lasting symptom relief from benign prostatic hyperplasiaShots:The company reported the new data from a survey of 2,000 American men aged ≥60 conducted by…
In an interview with PharmaShots, Meghan Scanlon, Senior Vice President and President for Urology and Pelvic Health at Boston Scientific shares her views on the completion of its $1.07B acquisition of Lumenis surgical businessShots:Boston Scientific reported the closing of its acquisition of the Lumenis surgical business from a BPEA affiliate for an upfront of $1.07B. The acquisition follows the Mar…

